30
Participants
Start Date
April 30, 2019
Primary Completion Date
May 28, 2022
Study Completion Date
November 16, 2022
Imlifidase
Imlifidase is an immunoglobulin G (IgG) degrading enzyme of Streptococcus pyrogenes that cleaves all 4 human subclasses of IgG with strict specificity.
Plasma Exchange
The subject's plasma is removed and discarded and the subject receives replacement donor plasma, albumin, or a combination of albumin and saline. IA may be used instead of PE to the discretion of the investigator. IA is achieved by passing a subject's plasma over columns that bind immunoglobulins and then the plasma is passed back to the subject.
Universitätsklinik für Innere Medizin III, Klinische Abteilung für Nephrologie MUW, Vienna
The Royal Melbourne Hospital, Melbourne
Royal Adelaide Hospital, Adelaide
New York University Grossman School of Medicine, New York
Charité-Universitätsmedizin. Dept. of Nephrology and Medical Intensive Care, Berlin
Medizinische Hochschule Hannover, Hanover
Hôpital Pellegrin, Bordeaux
CHU Grenoble Alpes - Néphrologie, dialyse et transplantation, Grenoble
Mayo Clinic, Rochester
Hôpital Saint-Louis. Service de Néphrologie et Transplantation, Paris
Hôpital Necker - Service de Néphrologie - Transplantation, Paris
Cedars-Sinai Medical Center, Los Angeles
Brigham and Women Hospital, Boston
Royal Prince Alfred Hospital, Sydney
Lead Sponsor
Hansa Biopharma AB
INDUSTRY